Abstract
Using a probabilistic model of the clinical and economic burden of rotavirus gastroenteritis (RVGE), we estimated the expected impact of vaccinating a US birth cohort with Rotarix in lieu of RotaTeq. Assuming full vaccination of all children, use of Rotarix - rather than RotaTeq - was estimated to reduce the total number of RVGE events by 5% and associated costs by 8%. On an overall basis, Rotarix would reduce costs by $77.2 million (95% CI $71.5-$86.5). Similar reductions with Rotarix were estimated to occur under an assumption of incomplete immunization of children.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Child, Preschool
-
Cost-Benefit Analysis
-
Female
-
Gastroenteritis / epidemiology
-
Gastroenteritis / prevention & control
-
Humans
-
Immunization / economics*
-
Infant
-
Infant, Newborn
-
Male
-
Models, Statistical
-
Rotavirus Infections / economics
-
Rotavirus Infections / epidemiology*
-
Rotavirus Infections / prevention & control*
-
Rotavirus Vaccines / economics*
-
Rotavirus Vaccines / immunology*
-
United States / epidemiology
-
Vaccines, Attenuated / economics
-
Vaccines, Attenuated / immunology
Substances
-
RIX4414 vaccine
-
RotaTeq
-
Rotavirus Vaccines
-
Vaccines, Attenuated